Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POXIPEN: Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction
NCT07027020Phase 3Recruiting
- Sponsor
- CHRU de Nancy - Hôpital Central
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in neurogenic bladder comparing IntraVesical Oxybutynin (IVO) with IntraVesical Placebo (PCB) (2 arms). Primary endpoint: Evolution of maximal bladder capacity at 4 weeks. Started Jan 2026; status: recruiting.
02
Drugs
oxybutynin
03
Conditions
neurogenic bladder
Beyond the preview
Go deeper on NCT07027020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07027020.